Compare Fabrinet (FN) vs Repligen Corporation Common Stock (RGEN) Price & Performance

FN trades at $427.82, down 6.26% over 24 hours, with a bullish technical signal despite near-term moving average weakness. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.10 exceeding expectations. Revenue grew to $3.42 billion in 2025, with net income of $332.53 million, and is projected to reach $4.6 billion in 2026. Analyst sentiment is positive, with 75% recommending Buy.

Outlook remains favorable due to surging AI data center demand and capacity expansion, though risks include customer concentration and high capital expenditures. The consensus price target of $769.50 implies significant upside, but investors should monitor margin pressures and competitive dynamics in the optical manufacturing sector.

RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.

Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.